Ads
related to: mymta beta blocker drugs
Search results
Results from the Go Local Guru Content Network
Legal status. In Wikidata. Beta blockers, also spelled β-blockers, are a class of medications that are predominantly used to manage abnormal heart rhythms ( arrhythmia ), and to protect the heart from a second heart attack after a first heart attack ( secondary prevention ). [1]
They are used as anti-arrhythmic drugs in patients with hyperthyroidism, cardiac dysrhythmia, atrial fibrillation, atrial flutter and ventricular tachycardia. The treatment with β-blockers reduces the incidence of sudden heart failure when the patient has already had a myocardial infarction.
Beta 1 blocker. Myocardial infarction (heart attack) Since beta 1 receptor are mainly located in the heart, most beta 1 blockers take abnormalities associated with the heart as the target. [5] It treats medical conditions like hypertension, arrhythmias, heart failure, chest pain, myocardial infarction.
MYmta, currently in a beta test phase, is available for download on Google Play and the Apple App Store.
The Metropolitan Transportation Authority (MTA) provides local and express bus, subway, and commuter rail service in Greater New York, and operates multiple toll bridges and tunnels in New York City. The Metropolitan Transportation Authority ( MTA) is a public benefit corporation responsible for public transportation in the New York City ...
MYmta is a mobile application-based passenger information display system developed by the Metropolitan Transportation Authority (MTA) of New York City. A beta version of the app was launched on July 2, 2018, and as of June 2019 [update] is still undergoing beta testing .
Beta adrenergic agonists or beta agonists are medications that relax muscles of the airways, causing widening of the airways and resulting in easier breathing. They are a class of sympathomimetic agents, each acting upon the beta adrenoceptors.
NMDA receptor antagonists are a class of drugs that work to antagonize, or inhibit the action of, the N -Methyl- D -aspartate receptor ( NMDAR ). They are commonly used as anesthetics for humans and non-human animals; the state of anesthesia they induce is referred to as dissociative anesthesia.
4-Methylthioamphetamine (4-MTA) is a designer drug of the substituted amphetamine class developed in the 1990s by a team led by David E. Nichols, an American pharmacologist and medical chemist, at Purdue University. It acts as a non-neurotoxic highly selective serotonin releasing agent (SSRA) in animals.
In 2018 only one β 3-AR agonist is approved by the European Medicines Agency (EMA) and the Food and drug Administration (FDA) as a medicine. The medicine is called Mirabegron and is used to treat OAB.